Zimmerman Eric I | AMiner学者主页

全面呈现 [Zimmerman Eric I] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（54）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Figure S4 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Sorafenib-induced keratinocyte toxicity in vivo.

2023

引用

AI阅读

2Supplementary Figure 8 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

Eric I. Zimmerman,Shuiying Hu,Justin L. Roberts,Alice A. Gibson,Shelley J. Orwick,Lie Li,Alex Sparreboom,Sharyn D. Baker

PDF file - 62K, Influence of Oatp1a/b-deficiency on sorafenib metabolism ex vivo.

2023

引用

AI阅读

3FIgure S1 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Sorafenib and sorafenib-N-oxide accumulate in human primary keratinocytes (HEKa) via a transporter-mediated process

2023

引用

AI阅读

4Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations During Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

Sharyn D. Baker,Eric I. Zimmerman, Yong-Dong Wang, Shelley Orwick, Douglas S. Zatechka,Jassada Buaboonnam,Geoffrey A. Neale,Scott R. Olsen,Eric J. Enemark,Sheila Shurtleff,Jeffrey E. Rubnitz,Charles G. Mullighan,

PDF file, 25K, Sorafenib and sorafenib N-oxide plasma concentrations.

2023

引用

AI阅读

5Supplementary Figure 6 from Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman,Justin L. Roberts,Lie Li, David Finkelstein,Alice Gibson,Amarjit S. Chaudhry,Erin G. Schuetz,Jeffrey E. Rubnitz,Hiroto Inaba,Sharyn D. Baker

PDF file, 76K, Identification of sorafenib glucuronide by high resolution mass spectrometry.

2023

引用

AI阅读

6Supplementary Methods from Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman,Justin L. Roberts,Lie Li, David Finkelstein,Alice Gibson,Amarjit S. Chaudhry,Erin G. Schuetz,Jeffrey E. Rubnitz,Hiroto Inaba,Sharyn D. Baker

2023

引用

AI阅读

7Table S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Percentage inhibition of kinases by tyrosine kinase inhibitors in a KiNative in situ assay.

2023

引用

AI阅读

8Supplementary Figure 5 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

Eric I. Zimmerman,Shuiying Hu,Justin L. Roberts,Alice A. Gibson,Shelley J. Orwick,Lie Li,Alex Sparreboom,Sharyn D. Baker

PDF file - 345K, Influence of Oatp1b2-deficiency on the liver-to-plasma ratio of sorafenib, sorafenib N-oxide, and sorafenib-glucuronide in vivo.

2023

引用

AI阅读

9Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations During Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

PDF file, 28K, Error rates and confidence levels for frequency of detection of FLT3 kinase domain mutations by next generation sequencing.

2023

引用

AI阅读

10Supplementary Table 4 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations During Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

Sharyn D. Baker,Eric I. Zimmerman,Yong-Dong Wang,Shelley Orwick, Douglas S. Zatechka,Jassada Buaboonnam,Geoffrey A. Neale,Scott R. Olsen,Eric J. Enemark,Sheila Shurtleff,Jeffrey E. Rubnitz,Charles G. Mullighan,

PDF file, 38K, Distribution of FLT3 kinase domain mutations on FLT3-ITD alleles.

2023

引用

AI阅读

11Supplementary Figure 2 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

Eric I. Zimmerman,Shuiying Hu,Justin L. Roberts,Alice A. Gibson,Shelley J. Orwick,Lie Li,Alex Sparreboom,Sharyn D. Baker

PDF file - 33K, Drug diffusion in PAMPA assay.

2023

引用

AI阅读

12Table S1 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Incidence of hand-foot skin reactions in patients treated with kinase inhibitors.

2023

引用

AI阅读

13Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations During Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

PDF file, 76K, Identification of FLT3 tyrosine kinase domain mutations.

2023

引用

AI阅读

14Supplementary Table 1 from Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman,Justin L. Roberts,Lie Li, David Finkelstein,Alice Gibson,Amarjit S. Chaudhry,Erin G. Schuetz,Jeffrey E. Rubnitz,Hiroto Inaba,Sharyn D. Baker

PDF file, 53K, Patient demographics and steady-state pharmacokinetics of sorafenib and metabolites.

2023

引用

AI阅读

15Table S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Percentage inhibition of kinases by tyrosine kinase inhibitors in a KiNative in situ assay.

2023

引用

AI阅读

16FIgure S1 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Sorafenib and sorafenib-N-oxide accumulate in human primary keratinocytes (HEKa) via a transporter-mediated process

2023

引用

AI阅读

17Figure S2 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Identification of OAT-dependent sorafenib transport in human primary keratinocytes

2023

引用

AI阅读

18Supplementary Figure 4 from Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman,Justin L. Roberts,Lie Li, David Finkelstein,Alice Gibson,Amarjit S. Chaudhry,Erin G. Schuetz,Jeffrey E. Rubnitz,Hiroto Inaba,Sharyn D. Baker

PDF file, 73K, Inhibition of UGT1A9-mediated sorafenib metabolism by azole compounds.

2023

引用

AI阅读

19Supplementary Figure 2 from Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman,Justin L. Roberts,Lie Li, David Finkelstein,Alice Gibson,Amarjit S. Chaudhry,Erin G. Schuetz,Jeffrey E. Rubnitz,Hiroto Inaba,Sharyn D. Baker

PDF file, 65K, Sorafenib metabolism by CYP and UGT enzymes.

2023

引用

AI阅读

20Figure S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

Eric I. Zimmerman,Alice A. Gibson,Shuiying Hu,Aksana Vasilyeva,Shelley J. Orwick,Guoqing Du,Gerard P. Mascara,Su Sien Ong,Taosheng Chen,Peter Vogel,Hiroto Inaba,Michael L. Maitland,

Evaluation of MKI kinase targets in human primary keratinocytes

2023

引用

AI阅读

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

Sharyn Baker合作论文数Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University;Comprehensive Cancer Center, The Ohio State University38

Alice A. Gibson合作论文数32

Hiroto Inaba合作论文数32

Orwick Shelley合作论文数26

Shuiying Hu合作论文数22

Alex Sparreboom合作论文数College of Pharmacy, The Ohio State University;Experimental Cancer Pharmacology Laboratory, The Ohio State University21

Roberts Justin L合作论文数20

Lie Li合作论文数19

Jeffrey Rubnitz合作论文数Menarini Stemline19

Aksana Vasilyeva合作论文数13

Gerard P. Mascara合作论文数11

Su Sien Ong合作论文数St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA11

Amarjit S Chaudhry合作论文数11

Guoqing Du合作论文数11

Erin Schuetz合作论文数St. Jude Children's Research Hospital11

Taosheng Chen合作论文数Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital11

Peter Vogel合作论文数Department of Pathology, St. Jude Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital;Comparative Pathology Core Laboratory, St Jude Children's Research Hospital11

David Finkelstein合作论文数Division of Medicine, Dentistry and Health Sciences, Florey Department of Neuroscience and Mental Health, University of Melbourne;Parkinson's Disease Laboratory, University of Melbourne;Florey Institute of Neuroscience and Mental Health11

Michael L. Maitland合作论文数Inova Schar Cancer Institute and University of Virginia11

Lee M Graves合作论文数Department of Pharmacology, University of North Carolina10

Jassada Buaboonnam合作论文数9

Geoffrey Neale合作论文数8

Sheila Shurtleff合作论文数St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA8

Eric Enemark合作论文数8

Olsen Scott R合作论文数8

Charles G. Mullighan合作论文数Department of Pathology, St. Jude Children's Research Hospital;Comprehensive Cancer Center, St. Jude Children's Research Hospital7

Yong-Dong Wang合作论文数St Jude Childrens Res Hosp, Dept Computat Biol, 332 N Lauderdale St, Memphis, TN 38105 USA4

Andrea V. Leisewitz合作论文数Department of Pharmacology, University of North Carolina @ Chapel Hill4

Jing Yang合作论文数Zhejiang University, Zhejiang University3

Claudia M Dollins合作论文数2

Brian J Dewar合作论文数2

Min Huang合作论文数2

Stephen V. Frye合作论文数Lineberger Comprehensive Cancer Center, School of Medicine, The University of North Carolina at Chapel Hill;Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill;Division of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill;Meryx Inc2

Ramachandran Abhijit合作论文数Mentrik Biotech, LLC;Dallas;Mentrik Biotech, LLC2

Cox Nathan J合作论文数2

Jones Shannon Z合作论文数2

Jian Jin (金坚)合作论文数School of Life Sciences and Health Engineering, Jiangnan University2

Kristy L. Richards合作论文数2

Scott M. Hammond合作论文数Asklepios BioPharmaceutical, Inc.;Lucidium Bio, Inc.2

Xinni Yuan合作论文数1

Steven Grant合作论文数1

Matthew J. Cooper合作论文数1

Sreerupa Ghose Roy合作论文数1

Michael S Roberts合作论文数1

Katja Schuster合作论文数1

Marty Whittle合作论文数1

martin c whittle合作论文数Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.1

j berk合作论文数1

Melissa Crawford合作论文数Ohio State Univ, Dept Internal Med, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43210 USA1

相似学者

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn